Navigation Links
Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
Date:5/8/2012

BELMONT, Calif., May 8, 2012 /PRNewswire/ -- Phalanx Biotech Group, a global genomic products and service provider, announces today the completion of manufacturing and testing for a proprietary targeted chromosomal microarray (CMA) designed specifically for prenatal and postnatal detection of microdeletions and microduplications related to a spectrum of congenital disorders, especially developmental and intellectual delay disorders. CytoOneArray® is capable of detecting 264 clinically confirmed disease regions and 41 subtelomere regions.

"Extensive testing from our CytoOneArray® manufacturing campaign demonstrates a quality product with high sensitivity, robustness, and reproducibility. We are extremely excited about offering our focused CMA at the time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test," said Shengwan Lee, Ph.D., President and CEO. "As the first in a series of CMA microarrays, Phalanx will continue to expand its line of clinical diagnostic products by leveraging its high performance microarray technology and innovative manufacturing processes."

CytoOneArray® resulted from extensive collaborations between leading cytogeneticists in Taiwan and Phalanx Biotech Group.  Through a comprehensive curation process of current, peer-reviewed and clinically confirmed disease regions, the Phalanx team designed probes to cover 90% of published microdeletions and microduplications associated with developmental and intellectual delay disorders. 

About Phalanx Biotech Group

Phalanx Biotech Group, with operations in California, Taiwan and China, provides genomics research products and services worldwide to academic, clinical, pharmaceutical and biotech communities. Built on world-class, integrated-chip foundry technology, Phalanx Biotech has developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes (human, mouse, rat, yeast and rice), microRNA (human, mouse, rat and plants), and custom targets.  Our highly-trained service specialists provide a comprehensive offering of gene expression and microRNA expression profiling services for biomarker discovery including sample preparation, expression analysis, and qPCR validation. For more information about our products and services, please visit our website at www.OneArray.com.

Contact
Vivien Mak, Ph.D., 1-650-320-8669 ext 103
vmak@onearray.com


'/>"/>
SOURCE Phalanx Biotech Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Phalanx Biotech Group Launches Rice Genome OneArray®
2. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Yongye Biotechnology International Retains CCG Investor Relations
5. ThirdBiotech Announces Kemeta as Newest Sponsor
6. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
8. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
9. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
10. China Kangtai Cactus Biotech Announces Record Second Quarter Results
11. Yongye Biotechnology International Announces Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... August 09, 2018 , ... MedEvolve, Inc. ... engagement and analytics software and services for physician practices, announced today the company’s ... history. After back-to-back record quarters in Q2 and Q3 last year, the company ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... announces research results on the significant impact of a proprietary biofield energy ... , The preclinical research assessed biomarkers for systemic and organ-specific inflammation, as ...
(Date:7/26/2018)... ... July 26, 2018 , ... Ariadne Afaganis, an evidence-based ... energy treated nutraceutical to improve anti-inflammatory and immune function responses. , Biomarkers for ... preclinical research, were significantly reduced. Results are as follows:, ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... for managing clinical trial patient and supplies data through its flagship IXRS® ... on IRT: Best Practices.” , This podcast features both Almac thought leaders and ...
Breaking Biology Technology:
(Date:7/26/2018)... ... July 25, 2018 , ... Boston ... executives on September 4, 2018 at The Hilton Boston Back Bay Hotel. This ... business development experiences and dissect the most relevant deals in biotech. , George ...
(Date:7/26/2018)... ... July 26, 2018 , ... The Conference Forum has confirmed the agenda for ... 24, 2018 at the Marriott Copley Place in Boston, MA. , Daniel Karlin, MD, ... as program chair to lead the discussion on how and when to implement mobile/digital ...
(Date:7/25/2018)... ... ... pioneering Duchenne muscular dystrophy clinical trial is now recruiting patients at two sites in ... the need to enroll patients. , “There is no cure for Duchenne, and ... a clinical trial,” said Catherine Jayasuriya, the founder and executive director of Coalition Duchenne, ...
Breaking Biology News(10 mins):